$OBIO

Hochman David P purchased $48K of OBIO

Hochman David P (See Remarks) purchased 10,000 shares of Orchestra BioMed Holdings, Inc. (OBIO) at $4.79 on 2026-09-03.

Original reporting
SEC EDGAR · Hochman David P
Published Sep 8, 2026, 12:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 12:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OBIO
Neutral
high confidence
Mentioned
$OBIO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OBIONeutralLow
01

Why it matters

The disclosed purchase adds a modest amount to insider holdings, offering limited insight for traders.

02

Market read

Routine insider purchase with minimal market impact.

03

What to watch

Potential upcoming corporate actions or upcoming data releases not disclosed.

Relevance 4/10Novelty 4/10Timing: today

Background

Orchestra BioMed Holdings (OBIO) is a biotech firm listed on NASDAQ. Insider transactions are regularly reported via Form 4.

Company-level read

Ticker impact

$OBIONeutralHigh confidence
Context

Form 4 filing shows insider David Hochman purchased 10,000 shares for $47,900, increasing his stake to over 1 million shares.

Expected impact

Minimal upward pressure, unlikely to move the stock significantly.

Evidence & confidence

Purchase size is modest relative to market cap and typical daily volume; insider already holds a large position.

Market effects

None; transaction is company-specific.

None; limited to the issuer.

None

Counterpoint

The purchase could signal confidence, but size is too small to be meaningful.

Key entities

  • Orchestra BioMed Holdings, Inc.

    NASDAQ-listed biotech company.

  • David P. Hochman

    Officer and director of OBIO.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

$DELLLow

Silver Lake Partners V DE (AIV), L.P. (Durban Egon) sold $15.0M of DELL (indirect holdings)

Silver Lake Partners V DE (AIV), L.P. sold 28,696 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $521.34 ($515.53–$529.16, $14.96M total) across 15 trades on 2026-09-04. Filed jointly with Silver Lake Technology Associates V, L.P. (Director), SLTA V (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).